

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): June 26, 2020**

**XBIOTECH INC.**

**(Exact name of Registrant as specified in its charter)**

**British Columbia, Canada**  
(State of Incorporation)

**001-37347**  
(Commission File Number)

**N/A**  
(I.R.S. Employer Identification No.)

**5217 Winnebago Ln, Austin, TX 78744**  
(Address of principal executive offices) (Zip Code)

**Telephone Number (512) 386-2900**  
(Registrant's telephone number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	XBIT	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The annual meeting of the stockholders of XBiotech Inc. (the “Company”) was held on June 26, 2020. The matters that were voted upon at the meeting, and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, are set forth below. Stockholders voted in accordance with the Board of Directors’ recommendations on each matter and voted to (1) elect five nominees for director; (2) ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020; and (3) ratify the amendments to the 2015 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by an aggregate of 2,500,000.

**Proposal #1 Election of five members of the Board of Directors**

	<b>For</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
John Simard	10,704,101	51,497	2,196,073
Jan-Paul Waldin	7,839,883	2,915,715	2,196,073
W. Thorpe McKenzie	9,146,845	1,608,753	2,196,073
Donald MacAdam	9,164,131	1,591,467	2,196,073
Peter Libby	10,715,897	39,701	2,196,073

**Proposal #2 Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020**

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
12,718,700	185,591	47,380	0

**Proposal #3 Ratification of the amendments to the 2015 Equity Incentive Plan to increase the number of shares authorized for issuance under the plan by an aggregate of 2,500,000.**

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
7,781,887	2,971,524	2,187	2,196,073

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2020

XBIOTECH INC.

By: /s/John Simard  
John Simard  
Chief Executive Officer and President